VaxIQ
PVPVaccine & Pathogen Immunology Knowledge Base
Precision Vaccines Program · Boston Children's Hospital
BCG
Live attenuated bacterial
Vaccine against tuberculosis and a key tool for neonatal immunization in endemic regions.
Hepatitis B
Recombinant protein subunit
Vaccine that protects against hepatitis B virus infection and its long-term complications, including cirrhosis and liver cancer.
mRNA-COVID-19
mRNA lipid nanoparticle
mRNA vaccine that protects against COVID-19 caused by SARS-CoV-2, including severe disease and hospitalization.
Yellow Fever (YF-17D)
Live attenuated viral
Live attenuated vaccine that protects against yellow fever, a viral hemorrhagic disease transmitted by mosquitoes in tropical regions.
Influenza (IIV/LAIV)
Inactivated / Live attenuated
Annual vaccine that protects against seasonal influenza, recommended for all individuals 6 months and older.
MMR
Live attenuated viral (trivalent)
Combined vaccine that protects against measles, mumps, and rubella — three highly contagious viral diseases.
HPV (Gardasil-9)
Virus-like particle (VLP)
Vaccine that protects against nine human papillomavirus types responsible for cervical cancer and genital warts.
Pneumococcal (PCV15/PCV20)
Conjugate
Vaccine that protects against invasive pneumococcal disease, including pneumonia, meningitis, and bloodstream infections.
Rotavirus (Rotarix/RotaTeq)
Oral live attenuated
Oral vaccine that protects against rotavirus, the leading cause of severe diarrheal disease in infants and young children.
Tdap
Toxoid + acellular subunit
Combination vaccine that protects against tetanus, diphtheria, and whooping cough (pertussis), including maternal immunization for newborn protection.
Polio (IPV/OPV)
Inactivated / Oral live attenuated
Vaccine that protects against poliovirus, a crippling and potentially fatal infectious disease targeted for global eradication.
Shingrix (RZV)
Adjuvanted recombinant subunit (AS01B)
Recombinant vaccine that prevents shingles (herpes zoster) and its complications in adults aged 50 and older.
Ebola (rVSV-ZEBOV)
Recombinant vesicular stomatitis virus
Licensed vaccine that protects against Ebola virus disease, used in outbreak response through ring vaccination strategy.
Malaria (R21/RTS,S)
Recombinant protein + adjuvant
Vaccine that protects against Plasmodium falciparum malaria, a leading cause of childhood mortality in sub-Saharan Africa.
Varicella (VZV)
Live attenuated viral
Vaccine that protects against chickenpox (varicella), a highly contagious viral infection caused by varicella-zoster virus.
Hepatitis A
Inactivated viral
Vaccine that protects against hepatitis A, a liver disease transmitted through contaminated food and water.
Haemophilus influenzae b (Hib)
Conjugate
Vaccine that protects against Haemophilus influenzae type b, a cause of bacterial meningitis and pneumonia in young children.
Meningococcal ACWY
Conjugate / Polysaccharide
Vaccine that protects against meningococcal disease caused by serogroups A, C, W, and Y, including meningitis and septicemia.
Meningococcal B (MenB)
Recombinant multicomponent
Vaccine that protects against meningococcal serogroup B, a leading cause of bacterial meningitis in adolescents and young adults.
Dengue (Dengvaxia)
Live recombinant chimeric
Vaccine that protects against dengue fever, a mosquito-borne viral disease caused by four distinct serotypes, recommended only for seropositive individuals.
Typhoid Conjugate (TCV)
Vi-polysaccharide conjugate
Conjugate vaccine that protects against typhoid fever, a systemic bacterial infection caused by Salmonella Typhi.
RSV (Adults/Maternal)
Prefusion F protein subunit / mRNA
Vaccine that protects older adults and newborns against respiratory syncytial virus (RSV), a leading cause of lower respiratory tract infections.
Rabies
Inactivated viral
Vaccine used for pre- and post-exposure prevention of rabies, a fatal viral neurological disease transmitted through animal bites.
Japanese Encephalitis
Inactivated viral (Vero cell-derived)
Vaccine that protects against Japanese encephalitis, a mosquito-borne viral brain infection prevalent in Asia and the Western Pacific.
Cholera (Oral)
Killed whole-cell oral
Oral vaccine that protects against cholera, a severe acute diarrheal disease caused by Vibrio cholerae, used in endemic and outbreak settings.
Mpox (JYNNEOS)
Modified vaccinia Ankara (MVA)
Vaccine that protects against mpox (monkeypox), a viral zoonotic disease related to smallpox, used in outbreak response and high-risk populations.
RSV (Nirsevimab/Pediatric)
Monoclonal antibody / mRNA (trial)
Monoclonal antibody and vaccine candidates that protect infants against respiratory syncytial virus (RSV), the most common cause of infant hospitalization.
HPV Bivalent (Cervarix)
VLP with AS04 adjuvant
Vaccine that protects against HPV types 16 and 18, the two strains responsible for the majority of cervical cancers.
HIV (Experimental)
Experimental (multiple platforms)
Experimental vaccine candidate against HIV, the virus that causes AIDS — no licensed product currently exists despite decades of research.
Tuberculosis (M72/AS01E)
Adjuvanted recombinant protein (AS01E)
Experimental vaccine candidate against tuberculosis, targeting adults with latent TB infection to prevent progression to active disease.
Hantavirus (Experimental)
Pathogen — No Licensed Vaccine
Rodent-borne viral pathogen that causes hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS) — no licensed vaccine available.
Marburg (Experimental)
Pathogen — No Licensed Vaccine
Highly lethal filovirus causing Marburg hemorrhagic fever — vaccine candidates are in early clinical trials with no licensed product.
Zika (Experimental)
Pathogen — No Licensed Vaccine
Mosquito-borne flavivirus linked to microcephaly and Guillain-Barré syndrome — vaccine candidates are in clinical trials with no licensed product.
Nipah (Experimental)
Pathogen — No Licensed Vaccine
Bat-borne paramyxovirus with a case fatality rate of 40–75%, classified as a WHO priority pathogen — vaccine candidates are in early trials.
Lassa Fever (Experimental)
Pathogen — No Licensed Vaccine
Rodent-borne arenavirus causing Lassa fever, endemic in West Africa — vaccine candidates are in Phase 2 trials with no licensed product.
Staphylococcus aureus (Failed)
Experimental — No Licensed Product
Common bacterial pathogen causing skin, bloodstream, and surgical site infections — multiple vaccine candidates have failed Phase 3 trials.
Norovirus (Experimental)
Virus-like particle (VLP)
Leading cause of acute gastroenteritis worldwide — virus-like particle vaccine candidates are in late-stage clinical trials.
VaxIQ AI Assistant
Coming SoonAsk questions about vaccine mechanisms, correlates of protection, metabolic signatures, and clinical implications.
AI-assisted · Grounded in PubMed · Launching soon — notify me